FDA expands approval of BioCryst's rare disease drug for use in young children

The U.S. Food and Drug Administration has expanded the use of BioCryst Pharmaceuticals' drug to include an oral pellet formulation for preventing hereditary angioedema attacks in children aged 2 to un... ...